Optimi Health OPTH 深 滬
等待開盤 09-25 09:30:00 美东时间
4.82
-0.140
-2.82%
華盛通- 最 高4.93
- 今 開4.93
- 成交量 2.05万股
- 最 低 4.76
- 昨 收 4.96
- 總市值 2759.87万
- 52周最高 6.40
- 市盈率 靜 --
- 換手率 0.36%
- 52周最低 4.00
- 委 比 98.64%
- 總股本 572.59万
- 歷史最高 6.40
- 量 比 0.37
- 振 幅 3.43%
- 歷史最低 4.00
- 每 手 1
- 風險率 0.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Optimi Health Completes Production Batch Of 5mg Naturally Derived Psilocybin Capsules, Manufactured End To End At cGMP Facility In Princeton, British Columbia
Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion and quality release of a production batch of 5mg naturally derived psilocybin capsules, manufactu...
09-23 21:03
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
Optimi Health Corp. appoints Dr. Michael Blough as Chief Clinical Development Officer to oversee Phase 2 psilocybin trial for major depressive disorder and Phase 3 MDMA trial for PTSD. Dr. Blough brings extensive experience in psychedelic clinical trials and will lead protocol execution, site activation, and regulatory interactions with Health Canada. Optimi aims to generate data to bring these treatments to underserved patient populations.
09-22 13:00
Optimi Health Plans To Initiate Multisite Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy For Individuals With Major Depressive Disorder In H1 2027, With Dosing Expected To Be Complete By 2027 End
Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027 Up to 200 participants at sites across Canada, among the largest studies of naturally derived psilocybin to date VANCOUVER, British Columbia, Sept. 10, 2...
09-10 20:51
SRX Global Management Team to Host Virtual Fireside Chat on July 14, 2026, and Issues Letter to Shareholders
SRX Global, Inc. announced a virtual Fireside Chat on July 14, 2026, at 10:30 a.m. ET, featuring CEO Kent Cunningham and Eric Jackson, discussing recent developments, the EMJX acquisition, and future vision. The event will include a 25-minute Q&A session for investors, with a replay available post-event. Additionally, SRX issued a shareholder letter highlighting the completion of the EMJX acquisition, a strong financial position with $55 million ...
07-10 12:30
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Optimi Health Corp. has completed its third commercial shipment of 5mg psilocybin capsules to Australia, where they are prescribed for treatment-resistant depression (TRD). The shipment included 1,000 capsules, produced in Canada under GMP standards, and is part of Optimi’s growing global supply to regulated markets. Australia became the first country to recognize psilocybin as a medicine for TRD in 2023. The company highlights expanding reimburs...
06-29 13:00
Optimi Health Completes Production Of Two Microdose Psilocybin Finished Drug Products, Formulated At 1 Mg And 2 Mg Dosages; Products Available To Authorized Clinical Research Organizations
Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant...
06-16 20:34
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Recent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access Ibogaine is under investigation to treat...
06-09 00:54
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Optimi Health Corp. has secured naturally derived ibogaine for its Ibogaine Initiative, with plans to develop finished drug products in 50mg and 100mg encapsulated forms at its GMP facility in Canada. Ibogaine, prioritized for accelerated FDA review under a recent U.S. executive order, is being studied for treating PTSD, opioid use disorder, and traumatic brain injury. The company aims to supply standardized dosages to support research and clinic...
06-08 12:00
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
The Therapeutic Goods Administration (TGA) in Australia has updated its framework for psychedelic-assisted therapy (PAT), expanding therapist eligibility, allowing treatment in diverse settings, and enhancing scalability. Optimi Health Corp., a Canadian psychedelic pharmaceutical company, supplies MDMA for PTSD and psilocybin for treatment-resistant depression under the updated Authorized Prescriber (AP) scheme. Key changes include multidisciplin...
05-29 12:30
首日收盘|Optimi Health收涨2485.03%，最新总市值0.35亿美元
Optimi Health涨2485.03%，最新市值0.35亿美元；Lincoln International涨12.60%，最新市值22.97亿美元；Research Alliance III涨3.00%，最新市值0.94亿美元；AMASS Brands (Direct Listing)跌33.24%，最新市值1.27亿美元；
05-21 06:00
